drugset / Trial / NCT00493545

Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

NCT00493545

Phase 1 Unknown 24 enrolled Nventa Biopharmaceuticals Corporation
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together

Timeline

Start
2007-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified
Subject VERPASEP CALTESPEN Vaccine